Am J Transplant, Volume 22, Suppl 3 Archives - Page 42 of 190 - ATC Abstracts

2022 American Transplant Congress
Surveillance with Allosure for Allograft Rejection and Infection in Lung Transplant
M. M. Botros¹, N. Sulejmani², B. F. Reader³, B. C. Keller¹
¹Pulmonary, Critical Care & Sleep Medicine, The Ohio State University, Columbus, OH, ²Medical Affairs, CareDx, South San Francisco, CA, ³Division of Transplant Surgery, The Ohio State University, Columbus, OH
*Purpose: Measurement of plasma donor-derived cell-free DNA (dd-cfDNA; AlloSure, CareDx) has been shown to be a useful non-invasive diagnostic test for injury and infection after…
2022 American Transplant Congress
Infectious Disease Testing Among US Deceased Organ Donors
A. Mezochow¹, T. Bittermann¹, E. Blumberg¹, R. Hasz², J. Anesi¹
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²Gift of Life Donor Program, Philadelphia, PA
*Purpose: Donor-derived infections are associated with significant morbidity in solid organ transplant recipients. To reduce the risk of donor-derived infections, the United Network for Organ…
2022 American Transplant Congress
Renal Allograft Rejection: New Paradigms in the T Cell Landscape Revealed by Single Cell RNAseq Analysis
T. Shi¹, A. Burg¹, K. Roskin², J. Rush³, B. Haraldsson³, A. Shields⁴, R. Alloway⁴, E. Woodle⁵, D. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Novartis Pharmaceuticals AG, Basel, Switzerland, ⁴Internal Medicine, University of Cincinnati, Cincinnati, OH, ⁵Surgery, University of Cincinnati, Cincinnati, OH
*Purpose: Defining the T cell landscape in renal allograft rejection (RAR) transcriptomically at the single cell level remains to be achieved. The purpose of the…
2022 American Transplant Congress
Impact of the COVID-19 Pandemic on CMS Organ Procurement Organization Performance Metrics
N. Dzebisashvili¹, K. Lentine², D. Axelrod³, K. Venkataramani¹, K. Axelrod¹, M. A. Schnitzler²
¹CareDx, South San Francisco, CA, ²Saint Louis University, St Louis, MO, ³University of Iowa, Iowa City, IA
*Purpose: CMS introduced new performance metrics for Organ Procurement Organizations (OPO). CDC death records define donation eligible deaths, the denominator of the donation and transplant…
2022 American Transplant Congress
Infections in Kidney Transplant Recipients on Belatacept versus Tacrolimus-Based Immunosuppression
S. Gattis¹, A. Basu²
¹Emory Healthcare, Atlanta, GA, ²Emory University Hospital, Atlanta, GA
*Purpose: Patients 70 years and older with advanced/ end stage kidney disease are increasingly receiving kidney transplants. Immediately post- transplant, our center utilizes Belatacept coupled…
2022 American Transplant Congress
Blood Transcriptomes of Kidney Recipients with Covid-19 Demonstrate Deficient Adaptive Immune Activation
K. Banu¹, Z. Sun², Y. A. Azzi³, M. M. Rana⁴, A. Reghuvaran¹, G. Carrara⁵, S. Hartell⁴, W. Asch¹, W. Zhang⁴, Z. Zhang², E. Akalin³, P. Cravedi², P. Heeger², K. Banu¹
¹Nephrology, Yale University, New Haven, CT, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Montefiore Medical Center, New York, NY, ⁴Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Icahn School of Medicine at Mount Sinai, New Haven, CT
*Purpose: Kidney transplant recipients (KTRs) have poor outcomes compared to non-KTRs with acute COVID-19. To provide insight into management of immunosuppression (IS) during COVID-19, we…
2022 American Transplant Congress
Optimal Development and Effector Function of Antibody-Suppressor CXCR5⁺CD8⁺ T Cells Requires Host IFN-γ and CD4⁺ T Cells
J. Zimmerer, S. Chaudhari, M. Hart, J. Han, K. Koneru, G. Bumgardner
OSUWMC, Columbus, OH
*Purpose: We reported the discovery of a novel subset of CXCR5+IFNγ+CD8+ T cells that suppresses antibody production (CD8+ TAb-supp cells). Alloprimed CD8+ TAb-supp cells significantly…
2022 American Transplant Congress
Why is Adolescent Waitlist Mortality Higher for Status 1A Girls?
J. Foutz¹, E. Hsu², S. Noreen³, M. Cafarella⁴, J. Pomposelli⁵, S. Biggins⁶, J. Reyes⁶, E. Perito⁷
¹Research, United Network for Organ Sharing, Richmond, VA, ²Seattle Children's Hospital, Seattle, WA, ³United Network for Organ Sharing, Richmond, VA, ⁴Policy and Community Relations, United Network for Organ Sharing, Richmond, VA, ⁵University of Colorado, Aurora, CO, ⁶University of Washington, Seattle, WA, ⁷UCSF, San Francisco, CA
*Purpose: Although adolescent pediatric liver transplant candidates are a vulnerable population, they are often excluded from analyses due to small sample size and assignment of…
2022 American Transplant Congress
Tocilizumab in Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: A Case Series
B. Boonpheng¹, R. Bakthavatsalam², C. D. Blosser¹, I. C. De Castro¹, I. Gimferrer³, Y. Ng¹, N. Leca¹
¹Nephrology, University of Washington, Seattle, WA, ²Surgery, University of Washington, Seattle, WA, ³Bloodworks Northwest, Seattle, WA
*Purpose: The optimal treatment for chronic active antibody-mediated rejection (ca-AMR) remains unclear. Tocilizumab (TCZ), a monoclonal antibody against IL-6, has been proposed in ca-AMR treatment…
2022 American Transplant Congress
Treatment of BK Virus with Weekly Intravenous Immunoglobulin in Adult Kidney Transplant Recipients
G. Girone¹, W. Asch²
¹Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Section of Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: The typical management of Polyoma BK virus (BKV) in kidney transplant recipients (KTR) includes reducing immunosuppression (IS). Intravenous immunoglobulin (IVIG) has been utilized for…